Buy KLOW Blend in Australia
KLOW is supplied in Australia by Australian Research Peptides, four peptides in one 80 mg vial working on damage and inflammation at the same time. GHK-Cu rebuilds collagen and the scaffolding holding cells together. BPC-157 and TB-500 push blood-vessel growth and cell movement into injured tissue. KPV, taken from the tail of alpha-MSH, blocks NF-kappaB and MAP kinase inflammatory signalling. The four dry together into one sealed cake, and post reaches all states and territories. For in vitro research purposes only.
Skin & Cellular Research · Lyophilised Powder · Batch-tested · SKU ARP-KLOW-80
$189.99
2+ vials: 5% off — applied automatically in the cart
Presentation
80 mg per vial
Grade
High-Purity Research Grade
Form
Lyophilised Powder
Category
Skin & Cellular Research
Currently out of stock — stocked lines dispatch same business day before 12pm AEST, Mon–Fri
Tracked shipping Australia-wide ·typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. Any amounts shown are reported from published studies, with the species or trial population named. ARP gives no dosing, medical or therapeutic guidance of its own.
KLOW · 80 mg
$189.99
Frequently Bought Together
About KLOW
All four peptides in a KLOW vial come out of preclinical research, and each has a separate literature behind it. GHK-Cu is examined in cell culture on collagen, elastin and the scaffolding that holds cells together. BPC-157 and TB-500 are examined in rodent repair models and in cell migration assays. KPV is examined in cultured human gut cells and in mouse colitis models, where the readout is inflammatory signalling. Combining them in one container is a packaging choice. Nothing here says four peptides sharing a vial act differently from four kept apart.
KLOW is a name, not a compound. Across this category the letters stand for the three peptides in GLOW, namely GHK-Cu, BPC-157 and TB-500, with KPV added as a fourth. Listings that spell out their contents commonly divide 80 mg into 50 mg of GHK-Cu and 10 mg each of the other three. That makes the copper peptide roughly five parts in eight, and ARP publishes the same nominal division for its own 80 mg vial. Since the letters describe no fixed recipe, two products carrying them can differ, and only the compound list and the quantity settle what either one is.
KPV is what separates KLOW from GLOW, and it is worth understanding on its own. It is a chain of three amino acids, lysine then proline then valine, taken from the tail end of alpha-MSH. Its published work sits in inflammation rather than in structural repair, which is why a four-peptide vial reaches across two research fields where a three-peptide one reaches across one. All four also hold their own listings in this catalogue, so the blend can be set against its own parts without leaving the site.
What is in the vial
| Component | Amount per vial |
|---|---|
| GHK-Cu — the copper(II) complex of the GHK tripeptide, and the largest component by mass in the blend | ~50 mg |
| BPC-157 — a fifteen-amino-acid peptide, sequence GEPPPGKPADDAGLV per PubChem CID 9941957 | ~10 mg |
| TB-500 — the seven-amino-acid actin-binding fragment of thymosin beta-4, not the full 43-residue protein | ~10 mg |
| KPV — Lys-Pro-Val, the C-terminal three residues of alpha-MSH, and the peptide that distinguishes KLOW from GLOW | ~10 mg |
| Total | 80 mg per vial |
Content reviewed
Further reading: Peptide Types, Categories and Blends · GLOW vs KLOW: What Is the Difference Between the Peptide Blends?
KLOW specifications, storage and shipping
- Compound: KLOW
- Also known as: GHK-Cu, BPC-157, TB-500 and KPV combination
- Class: Four-peptide blend
- Appearance: Lyophilised powder
- Sizes & SKUs: 80 mg (ARP-KLOW-80)
- Presentation: sealed glass vial
- Form: Lyophilised Powder
- Grade: High-purity research grade
- Purity verification: HPLC-assayed on every batch to a minimum of 99% purity — the measured result for your batch is stated on its Certificate of Analysis
- Identity confirmation: Mass spectrometry
- Classification: In vitro research purposes only — laboratory reference material
- Lyophilised — long term
- −20 °C to −80 °C — long-term storage
- Lyophilised — short term
- 2–8 °C — refrigerated, for a few months
- Reconstituted
- 2–8 °C — use within 8–12 weeks
Every batch undergoes HPLC purity analysis and mass-spectrometry identity confirmation. No laboratory report is published for this line yet. The COA library lists every product and strength, and says which reports are available.
This line is currently out of stock. Stocked lines ordered before 12pm AEST on a business day are dispatched the same day with tracked, discreet shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about KLOW
This question guide from Australian Research Peptides covers KLOW in Australia: what the listing contains, live buying and delivery questions, research context, handling, testing and comparisons. Start with the quick answers, then open the topic group that matches your search.
Buying, price and availability
KLOW is dispatched anywhere in Australia by Australian Research Peptides, and Express Post reaches all states and territories with tracking on either service. One sealed vial holds the four-peptide cake of GHK-Cu, BPC-157, TB-500 and KPV, each of which also has its own ARP listing. There is no KLOW vial to send right now, though the weekday 12pm AEST cut-off holds once one is back, moving entirely within Australia, so customs never sees the parcel.
The address entered on a KLOW stock alert is used for that one message and nothing else — no newsletter, no promotions, no sharing with anyone. It is a single-purpose record against a single product line, and it is not the same thing as having an account or a marketing subscription.
KLOW comes from Australian Research Peptides Pty Ltd, an Australian company selling direct rather than reselling an overseas listing. Each lot is HPLC-tested before release, and ARP's CoA library records which products and strengths have a certificate published. ARP also publishes a component table naming all four peptides in the vial. Orders settle by PayID or bank transfer and post nationwide — and once a vial is back, one beating 12pm AEST leaves that business day.
KLOW carries one Australian-dollar figure for the vial, and there is no second size to compare it against — the 80 mg vial is the whole listing. That figure, together with whether the vial can ship today, is read live from Australian Research Peptides' stock and price records. Qualifying peptide lines pick up ARP’s automatic multi-vial discount at two or more on a line, with no code to enter.
KLOW is ordered from Australian Research Peptides online, with no phone line to call and no counter to visit. The four-peptide vial comes in a single 80 mg size, so there is one stock position to follow rather than several. Payment is by PayID or by bank transfer and by nothing else, so no card details change hands. Delivery is tracked, to any Australian address.
The KLOW blend comes from Australian Research Peptides and Chemist Warehouse does not carry it, nor does any pharmacy line resemble it. The blend brings four research peptides together in one vial and not one of them is approved for supply in Australia. ARP lists it as a single 80 mg research vial.
Identity, names and exact format
KLOW is a four-peptide blend supplied as a single freeze-dried cake. Inside it are GHK-Cu, BPC-157, TB-500 and KPV. Those are the three peptides GLOW holds, plus KPV, which is where the leading K in the name comes from. Three of them sit in tissue-repair research and KPV sits in inflammation research, so one vial reaches into two fields rather than one.
There is no single count for KLOW, because four separate chains share the vial. BPC-157 is fifteen, sequence GEPPPGKPADDAGLV in PubChem. The TB-500 fragment is seven, LKKTETQ, sitting at positions 17 to 23 of mature thymosin beta-4. GHK is three, glycine then histidine then lysine. The copper rides on that chain and is not itself an amino acid. KPV is three, lysine then proline then valine.
KPV is the peptide that pulls KLOW toward inflammation research. It is lysine, proline and valine, the final three amino acids of alpha-MSH. Work published in Gastroenterology in 2008 reports 10 nM KPV blocking NF-kappaB and MAP kinase signalling in cultured human gut and T cells. Female C57BL/6 mice in the same study drank 100 µM KPV, which cut the incidence of colitis in two models.
A KLOW vial from Australian Research Peptides holds 80 mg in total, blended at the standard KLOW ratio, so it is about 50 mg of GHK-Cu with about 10 mg each of BPC-157, TB-500 and KPV. That is what the name denotes across this category and it totals the 80 mg on the label. Read those as nominal formulation figures rather than an assayed result for this vial. If the exact division matters for the work, ask before ordering.
One of KLOW's four peptides is GHK-Cu, and the copper ion at the centre of that complex carries a strong blue colour into both the powder and the solution. So a blue KLOW vial is the expected appearance rather than a fault. Cloudiness, particles or undissolved material are the things worth questioning.
KLOW is supplied as one vial, not as four vials packed together. The peptides are freeze-dried into a single cake inside one sealed, tamper-evident glass vial, and they cannot be separated once combined. If the work needs them apart, Australian Research Peptides sells each of the four on its own listing, and GLOW covers three of them in a single vial.
Research context and evidence
KLOW has no single mechanism, because four peptides act four ways. GHK-Cu binds copper and is examined in cell culture on collagen and elastin synthesis. TB-500's seven-amino-acid motif binds actin, and a 2003 FASEB Journal paper found that motif essential to the parent protein's activity in endothelial assays. BPC-157 is described in rodents acting through Akt-eNOS and VEGFR2 signalling. KPV enters cells through a peptide transporter and blocks inflammatory signalling there.
No published study tests KLOW as a blend. Each peptide carries its own preclinical file. BPC-157 has rodent tendon, muscle, bone and gut models behind it, and three small human studies. In Philp's 2003 FASEB Journal work, TB-500's actin motif matched the whole protein at around 50 nM in endothelial migration assays and chick aortic arch sprouting. Soluble actin at 5 to 50 nM shut down that sprouting. None of it reports a human result.
Two of KLOW's four peptides have published animal doses, both from Biçer's 2026 rat tendon study. Rats with repaired Achilles tendons received BPC-157 at 10 µg/kg/day. A separate arm received TB-500 at 60 µg/kg/day. Injections went into the abdominal cavity daily, for four weeks after surgery. Thirty-two male Sprague-Dawley rats filled four groups of eight. Every figure there belongs to a rat, not to a person.
KLOW's GHK-Cu component was tested at picomolar concentrations in cultured fibroblasts. A 1988 FEBS Letters paper measured collagen synthesis against dose. Stimulation began between 1 and 10 pM and peaked at 1 nM. Cell numbers did not change, so the peptide was acting on synthesis rather than on growth. Those are concentrations in a dish, not amounts given to a living animal.
KLOW carries four peptides and not one shared elimination figure. Only BPC-157 has a published plasma number, beneath thirty minutes, per Mateescu's 2026 Pharmaceutics review. The thymosin fragment, the copper tripeptide and KPV each lack that measurement in people. Nothing in the literature describes what a four-way mixture does once it enters circulation, so a stated duration would be fabrication dressed as evidence.
There is no published answer for KLOW as a formulation, and the four component literatures do not combine into one. The rodent work behind BPC-157, TB-500 and KPV measured across days to weeks; the controlled GHK-Cu studies ran roughly twelve weeks topically. Averaging four preclinical timescales does not produce a human one.
No discontinuation data exists for KLOW whatsoever. Its four peptides have never been trialled together in people, and the separate literatures are animal and cell studies that quit measuring the moment treatment ends. Nothing documents a rebound, a comedown, or a fading of effect later on. A four-way mixture multiplies unknowns rather than settling them, and no supplier can honestly claim otherwise.
KLOW combines four peptides, none of which has published controlled human injectable safety data. There is therefore no measured side-effect profile for KLOW, and stacking four uncharacterised compounds multiplies the unknowns rather than averaging them. GHK-Cu's human evidence is topical only and does not extend to this preparation.
Handling, storage and measurements
An eighty-milligram KLOW vial carries a visible quantity by any measure, and the GHK-Cu fraction runs a blue tone through the dried mass, so the concern rarely arises. What buyers do report instead is a cake broken loose and rattling as fragments. Freeze-dried solids are brittle and travel poorly intact; fractured material dissolves exactly as an undisturbed one does.
Every peptide in a KLOW vial contains lysine, so the whole powder pulls in moisture. Keep the sealed vial dry, dark and cold, below -15 °C for anything long-term. Let it reach room temperature in a desiccator before you open it. Only the TB-500 part carries glutamine, one of the five amino acids that make holding a peptide in solution risky. Reconstituted material is therefore not for keeping.
KLOW dissolves as one powder rather than as four separate steps. Bacteriostatic water is the usual diluent. One diluent dissolves the lot, rather than four separate preparations. Run it down the inside wall of the vial instead of straight onto the cake, then swirl gently rather than shaking. Whatever volume goes in fixes the strength of the solution. Keep the result cold and split it into aliquots.
Reconstituted KLOW carries Australian Research Peptides' chilled life of 8 to 12 weeks at fridge temperature, 2-8 °C, with the earliest of its four peptides to degrade setting that date for all of them. Only the TB-500 component finishes on glutamine, which Bachem names among the residues that shorten a peptide in solution; the other three carry none of them. An 80 mg vial is a lot to get through.
Two millilitres of bacteriostatic water into an 80 mg KLOW vial gives 40 mg/mL. Four millilitres gives 20 mg/mL and eight gives 10 mg/mL. Divide the vial's milligrams by the millilitres added for any other figure. That result covers all four peptides together. The per-component amounts listed on this page are the recipe the KLOW name carries rather than a measurement taken from the vial in front of you, so they will not divide into four trustworthy separate concentrations. A calculator in the Australian Research Peptides guides does the same division.
KLOW dries four peptides into one cake, and that dissolves more slowly than any single compound, so the intermediate stage can look wrong when it is not. Copper supplies the blue tint, which should remain see-through. Bubbles raised by handling fade without help. Material still suspended once the liquid has warmed and settled is undissolved solid, and a preparation like that should be discarded.
KLOW arrives as a dry cake and needs bacteriostatic water for laboratory work in solution. Bacteriostatic water is ordinarily chosen for that, and its label records benzyl alcohol added as a preservative so a container can be drawn from more than once. Australian Research Peptides puts it in Lab Supplies, on its own line away from the peptides. It forms no part of what a KLOW vial holds.
An 80 mg KLOW vial is 80,000 micrograms of combined peptide spread across four compounds, so a 1 mg draw contains a fraction of each rather than 1 mg of any one. That gives eighty draws at 1 mg of blend. Australian Research Peptides blends KLOW at about 50 mg of GHK-Cu against about 10 mg each of BPC-157, TB-500 and KPV, so a draw carries the four in roughly that proportion rather than an equal share.
Testing and batch documents
Every KLOW batch is tested before Australian Research Peptides supplies it, and four peptides make that job harder than one. Liquid chromatography has to resolve four components instead of a single main peak. Mass spectrometry has four expected masses to account for rather than one. No matching certificate is currently published for this product and strength.
Ordering, payment and Australian delivery
One KLOW vial lands just under the free Standard tracked post mark — close enough that adding the bacteriostatic water it needs anyway usually carries the order over. Two vials clear both that threshold and the higher Express Post one in a single step, which no other four-peptide order in Australian Research Peptides' range manages. Qualification is judged on the pre-discount subtotal, so the multi-vial reduction can never push an order back below either mark.
A KLOW parcel is 1–2 business days away by Express Post in the fastest states, up to four in the slowest, and 2–5 by standard tracked post. Australian Research Peptides' delivery checker returns an estimate against a specific postcode rather than a capital-city average. Transit figures are the carrier's, counted in business days after lodgement, and they are estimates rather than guarantees.
PayID is a bank-run service, not a third party: it maps a phone number, email or ABN to an existing Australian bank account so a KLOW payment moves directly between banks over the New Payments Platform. You initiate it inside your own banking app, and Australian Research Peptides receives money without ever holding a payment credential of yours. The order reference goes in the description, because that is the only thing tying the transfer to the order.
At 80 mg, KLOW is the second-largest vial in the catalogue and takes diluent to match — enough that a 3 mL bacteriostatic water vial would be consumed by one reconstitution at most working concentrations. The 10 mL is the practical pairing. Insulin syringes are the other item, and neither ships with the vial.
Access, approval and sport questions
Two of KLOW's four peptides are scheduled. BPC-157 and TB-500 each sit in Schedule 4 of the federal Poisons Standard, so both are prescription only, and both are named again at Appendix D clause 5, the list of poisons nobody may possess without authority. KPV and GHK-Cu are on neither. Australian Research Peptides supplies KLOW as laboratory research material and gives no legal advice.
KLOW is not an approved medicine in America or in any other jurisdiction, and neither is any of its four peptides taken singly. No authority has reviewed a four-peptide mixture of this shape for safety, quality or effectiveness. Approval attaches to one defined product, made to one standard, for one stated indication. A research blend satisfies none of those conditions.
KLOW is banned in sport because at least two of its four peptides are — BPC-157 under S0, TB-500 among the S2 growth factors. KPV and GHK-Cu are named nowhere, which settles less than it appears. A tested competitor gains nothing from the mixture, since one prohibited component in a sample is sufficient. Sport Integrity Australia is the Australian authority.
Importing KLOW raises a question that does not stop at the border, because two of its four peptides carry a possession restriction as well as an import one. BPC-157 and TB-500 are both named at Appendix D clause 5 of the Poisons Standard, the list of poisons a person may not possess without authority. KPV and GHK-Cu appear on neither. An Australian Research Peptides order is posted within Australia and imports nothing.